arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

VivoSim Labs, INC.

VIVS
$0.44 ▲ +0.11 (+33.54%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
70 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
25
Health
Poor
Neutral Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, VivoSim Labs, INC. shows mixed fundamentals. Return on Invested Capital remain bright spots. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap
Dividend Yield
Revenue Growth -21.6%
Op. Margin None
ROIC 229.1%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

70-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$40.00K
↓ -21.6%
Net Income Profit after all expenses
$-5.76M
↓ -114.2%
Operating Margin Operating profit as % of sales
-127.5%
↑ +60.2%
FCF / Share Free cash flow per share
$-0.87
↑ +4.6%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • Return on Invested CapitalReturn on Invested Capital of 1045.4% is excellent on an absolute basis (target > 10%)
warning

Bearish Risks

  • Interest CoverageInterest Coverage of -957.25x is weak on an absolute basis (target > 5x)
  • FCF / Net IncomeFCF / Net Income of 0.78x is caution on an absolute basis (target > 1x)

Health Breakdown

Financial Health
18
Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 70 quarters